The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes
[5] Some patients with obesity may have mild elevations in cortisol or altered cortisol metabolism related to their weight status, and substantial weight loss could potentially normalise these patterns, though evidence for this specific effect is limited
Combined Approach: Statin for cholesterol: -40% LDL ACE inhibitor for BP: -10 mmHg Retatrutide for weight/BP/lipids: -14 mmHg BP, -15% cholesterol, -28.7% weight Together, these interventions provide additive cardiovascular protection exceeding any single agent
administered alpha-melittin nanoparticles (-MEL-NPs) and injected intravenously with a concentration of 20 mg/kg which showed the growth inhibition of B16F10 (human melanoma cells) and have no toxic effects on normal cells (209)
However, L-glutamine therapy did not change either the Hb or the reticulocyte counts significantly when compared to the placebo group
